We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00887809
First Posted: April 24, 2009
Last Update Posted: January 25, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
Results First Submitted: December 21, 2015  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Sarcoma
Leiomyosarcoma
Malignant Fibrous
Histiocytoma
Angiosarcoma
Interventions: Drug: gemcitabine
Drug: docetaxel
Drug: bevacizumab

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Gemcitabine, Docetaxel, Bevacizumab Gemcitabine, Docetaxel, Bevacizumab
Gemcitabine, Docetaxel, Placebo Gemcitabine, Docetaxel, Placebo

Participant Flow:   Overall Study
    Gemcitabine, Docetaxel, Bevacizumab   Gemcitabine, Docetaxel, Placebo
STARTED   37   10 
COMPLETED   33   10 
NOT COMPLETED   4   0 
Patient Not Treated                3                0 
Death                1                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Gemcitabine, Docetaxel, Bevacizumab Gemcitabine, Docetaxel, Bevacizumab
Gemcitabine, Docetaxel, Placebo Gemcitabine, Docetaxel, Placebo
Total Total of all reporting groups

Baseline Measures
   Gemcitabine, Docetaxel, Bevacizumab   Gemcitabine, Docetaxel, Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 37   10   47 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   26   7   33 
>=65 years   11   3   14 
Gender 
[Units: Participants]
     
Female   22   2   24 
Male   15   8   23 


  Outcome Measures

1.  Primary:   Overall Objective Response   [ Time Frame: 6 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. William Tap
Organization: Memorial Sloan Kettering Cancer Center
phone: 646-888-4163
e-mail: tapw@mskcc.org



Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00887809     History of Changes
Other Study ID Numbers: 09-015
First Submitted: April 23, 2009
First Posted: April 24, 2009
Results First Submitted: December 21, 2015
Results First Posted: January 25, 2016
Last Update Posted: January 25, 2016